Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | GBP | Delayed | ||
| BATS Europe | SEK | Delayed | ||
| NASDAQ | USD | Real-time | ||
| OTC Markets | USD | Delayed | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
AstraZeneca Plc (NASDAQ: AZN) reported topline data from the DESTINY-Breast02 phase 3 trial of Enhertu (trastuzumab deruxtecan).The trial evaluated Enhertu versus...
By Sruthi Shankar (Reuters) -UK's FTSE 100 edged up on Monday as gains in drugmaker AstraZeneca (NASDAQ:AZN) and consumer stocks relieved pressure from mining and oil heavyweights...
By Peter Nurse Investing.com - European stock markets largely edged higher Monday, starting the new week on a cautious note as investors digested weak Chinese economic data.By...
Pharma giant AstraZeneca (GB:AZN) became a globally famous name thanks to its COVID vaccine and is among the biggest companies in the FTSE 100 - not to mention the fact that its...
LONDON, July 20, 2022 (GLOBE NEWSWIRE) -- The “HER2-Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2028” report offered by GlobalData provides an overview of...
LONDON, July 05, 2022 (GLOBE NEWSWIRE) -- The “Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report offered by...
AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 5.95 | 5.95 | 5.95 | 0.00 | 0.00% | 0.00 | London | |||
| 0.94 | 1.20 | 0.94 | 0.00 | 0.00% | 0.00 | London | |||
| 1,657.50 | 1,661.50 | 1,650.00 | -2.5 | -0.15% | 372.09K | London | |||
| 217.60 | 219.40 | 215.20 | -1.40 | -0.64% | 3.97M | London | |||
| 120.58 | 120.58 | 116.88 | +2.48 | +2.10% | 13.18M | London | |||
| 175.55 | 177.05 | 175.10 | -0.05 | -0.03% | 7.04M | London | |||
| 373.00 | 379.50 | 370.00 | -2.00 | -0.53% | 57.25K | London | |||
| 81.40 | 82.60 | 79.00 | -3.80 | -4.54% | 229.93K | London | |||
| 0.00 | 0.00 | 0.00 | 0.0000 | 0.00% | 0.00 | London | |||
| 409.00 | 410.00 | 409.00 | +1.00 | +0.24% | 28.57K | London | |||
| 359.00 | 363.00 | 357.00 | -0.60 | -0.17% | 1.80M | London | |||
| 1,151.50 | 1,160.00 | 1,143.50 | +12.00 | +1.05% | 2.49M | London | |||
| 620.00 | 620.00 | 620.00 | 0.00 | 0.00% | 12.95K | London | |||
| 1.83 | 2.502 | 1.50 | 0.000 | 0.00% | 0.00 | London | |||
| 33.50 | 33.50 | 33.50 | 0.000 | 0.00% | 52.42K | London |